

Sneak Pre-View of TCT-2012

Late Breaking Trials

1st Reports & Featured Research

George D. Dangas, MD, PhD, FACC, FSCAI, FAHA
Co-Director, TCT
Professor of Medicine (Cardiovascular Disease)
Mount Sinai School of Medicine, NYC

Day-1

- **FAME-2 Cost-Effectiveness**
 - N=1220 pts with lesions $FFR < 0.80$
 - Randomized PCI+OMT vs OMT
- **MASTER**
 - N=433 pts with STEMI, having 1° PCI
 - Randomized MGuard (mesh) Stent vs any DES/BMS per operator choice
 - Primary endpoint $>70\%$ ST-resolution
- **ISAR-Left Main-2**
 - N=650 pts unable or unwilling to have CABG
 - Randomized to EES vs ZES
 - Primary endpoint: 1-year MACE (d/MI/TLR)

Day-2

- **RESPECT: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Stroke**
 - N=980 pts with 2.8 year average f/u
 - I° endpoint : non-fatal CVA, post-randomization death or fatal ischehmic CVA
- **The PC Trial: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Embolism**
 - N=414 pts with over 2.5 years f/u
 - I° endpoint : death, nofatal CVA, peripheral embolization
- **A Prospective, Randomized Trial of Sliding-Scale Hydration for Prevention of Contrast Nephropathy (I° endpoint 25% or >0.5mg/dl rise in serum creatinine)**
 - N=396 pts with eGFR<60ml.min/1.73m2. Both groups received 0.9% saline at 3 mL/kg for at least one hour prior to cath.
 - The standard hydration group was hydrated at 1.5 mL/kg/hr.
 - In the LVEDP group, the fluid rate was adjusted according to the LVEDP as follows:
 - 5 mL/kg/hr for LVEDP <13 mmHg;
 - 3 mL/kg/hr for 13-18 mmHg;
 - 1.5 mL/kg/hr for >18 mmHg.

Day-3

- **XIMA trial: BMS vs DES in Patients > age of 80**
 - N=800
 - Bare Metal Vision Stent Vs Drug-eluting Xience Stent in the Management of Angina in the very elderly
 - I° endpoint: MACE or major hemorrhage at 1-year f/u
- **Drug Eluting Stent In-Stent Restenosis: 3 Treatment Approaches (ISAR-DESIRE 3)**
 - N=402 with DES ISR after ‘limus” type DES
 - Randomized Trial of Paclitaxel-Eluting Balloon vs. Paclitaxel-Eluting Stent vs. Plain Balloon Angioplasty
 - I° endpoint; In-segment % diameter stenosis at 6-8 month f/u
- **STEMI-RADIAL Trial**
 - N=707 with STEMI having primary PCI
 - I° endpoint : Major Bleeding by HORIZONS definition or vascular access complications

1st Reports Highlights - 1

- **PARTNER B (inoperable AS)**
 - 3-year results
- **TRILOGY-ACS Angiographic Cohort**
 - Prasugrel vs Clopidogrel in medically Tx ACS
- **PAD of Popliteal artery: PTA vs Nitinol Stent implantation**

1st Reports Highlights - 2

- **ADAPT-DES 1-year** results
 - Stent thrombosis impact of High PRU (clopidogrel resistance)
- **AIDA MRI** substudy in STEMI
 - Intracoronary Abciximab vs Placebo
- **Post-Conditioning in STEMI** treatment with 1^o PCI: prospective, randomized evaluation

Featured Clinical Research - 1

- **FIM 18F Direct-Flow AoValve**
 - N=45, critical AS, logEuroscore >20
- **FIM TAVR with Portico AoValve**
 - N=20
- **REOPEN AMI randomized study**
 - N=240 Adenosine Vs Nipride after aspiration thrombectomy in STEMI PCI
- **Rosuvastatin vs Placebo for prevention of Tnl elevation post-PCI**
 - N=1752
- **SUPPORT-1: FIM Randomized Evaluation of CMX-2043, a Lipoic Acid-Based Cytoprotectant, to Reduce PCI-Myonecrosis**
 - N=142 dose finding
- **DEB evaluation before SFA/popliteal stenting**
 - N=104 randomized
- **STOP-IC Impact of clistazol on angiographic restenosis after endovascular treatment for femoropopliteal lesions**
 - N=200 randomized
- **Prevention of CIN in STEMI PCI**
 - N=500 randomized 1-1-1-1 according to n-AC, NaHCO₃, both or neither

Featured Clinical Research - 2

- **PARADOX**: Smoking Effect On The Pharmacodynamics of Prasugrel and Clopidogrel in PCI patients
 - N=110, crossing over between the 2 drugs after 14-day washout
- **Prasugrel vs VASP-tailored clopidogrel Rx** in ACS-PCI pts
 - N=177 randomized
- **J-DESsERT**: Japanese prospective, randomized, multi-center trial comparing paclitaxel-eluting stents and sirolimus-eluting stents in patients with coronary artery disease eligible for PCI
 - N=3553 randomized
- **PARIS-1 year**: Clopidogrel Cessation and Non-adherence on Adverse Events Following PCI
 - N=5033 Registry
- **PADN-1**; Pulmonary Artery Denervation For The Treatment Of Pulmonary Artery Hypertension Refractory To Medication
 - N=12 Registry
- **NANOM FIM**: Plasmonic Photothermal Therapy of Atherosclerotic Lesions (Athero-destruction) with Silica-Gold Nanoparticles
 - N=180 randomized

Summary

- **Diverse Subjects will be addressed at TCT-2012 LBCT, 1st reports % Featured Research Sessions**
 - **PFO CLOSURE**
 - **Coronary PCI**
 - **STEMi**
 - **FFR-guided PCI**
 - **DES-ISR**
 - **LM**
 - **CIN prevention**
 - **Post-PCI myonecrosis**
 - **Antiplatelet Therapies**
 - **PAD popliteal and SFA stenting**
 - **TAVR**